State of Wyoming Has $385,000 Stake in Royalty Pharma plc (NASDAQ:RPRX)

State of Wyoming increased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 129.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 15,096 shares of the biopharmaceutical company's stock after acquiring an additional 8,518 shares during the period. State of Wyoming's holdings in Royalty Pharma were worth $385,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brooklyn Investment Group raised its holdings in Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 876 shares in the last quarter. Allworth Financial LP raised its holdings in Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 877 shares in the last quarter. Riverview Trust Co raised its holdings in Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 1,186 shares in the last quarter. Fifth Third Bancorp raised its holdings in Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 997 shares in the last quarter. Finally, Rakuten Securities Inc. raised its holdings in Royalty Pharma by 160.5% during the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 1,003 shares in the last quarter. Institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Performance

NASDAQ:RPRX traded up $0.14 on Friday, hitting $32.45. The company's stock had a trading volume of 2,514,291 shares, compared to its average volume of 3,476,979. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a fifty day moving average of $32.40 and a two-hundred day moving average of $30.19. The firm has a market capitalization of $18.71 billion, a P/E ratio of 22.38, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.32.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.07. The firm had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.71%. The ex-dividend date of this dividend is Friday, May 16th. Royalty Pharma's payout ratio is 47.57%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RPRX. Morgan Stanley began coverage on Royalty Pharma in a report on Friday, May 16th. They set an "overweight" rating and a $51.00 target price on the stock. Wall Street Zen lowered Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Tuesday, May 20th. Finally, Citigroup restated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.